Product Description
E-selectin antibody. (Sourced from: https://www.sec.gov/Archives/edgar/data/1253689/000155837021002222/glyc-20201231x10k.htm)
Mechanisms of Action: SELE Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Anemia, Sickle Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04255875 |
C4071001 | P1 |
Completed |
Anemia, Sickle Cell |
2023-07-07 |
23% |
2023-08-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/08/2023 |
News Article |
Sickle Cell Disease Treatment Market Worth $4.69 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners |